Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Maria-Victoria Mateos, Jenna D. Goldberg, Ajai Chari, Arnob Banerjee, Lotfi Benboubker, Raluca Verona, Jeffrey R. Infante, Tara Stephenson, Jesús F. San-Miguel, Alfred L. Garfall, Yusri Elsayed, Manisha Bhutani, Hareth Nahi, Lionel Karlin, Niels W.C.J. van de Donk, Suzette Girgis, Saad Z. Usmani, Lixia Pei, Laura Rosiñol, Albert Oriol, Amrita Krishnan
Publikováno v:
The Lancet, 398(10301), 665-674. Elsevier Limited
Usmani, S Z, Garfall, A L, van de Donk, N W C J, Nahi, H, San-Miguel, J F, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, L, Verona, R, Girgis, S, Stephenson, T, Elsayed, Y, Infante, J, Goldberg, J D, Banerjee, A, Mateos, M-V & Krishnan, A 2021, ' Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study ', The Lancet, vol. 398, no. 10301, pp. 665-674 . https://doi.org/10.1016/S0140-6736(21)01338-6
LANCET
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Usmani, S Z, Garfall, A L, van de Donk, N W C J, Nahi, H, San-Miguel, J F, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, L, Verona, R, Girgis, S, Stephenson, T, Elsayed, Y, Infante, J, Goldberg, J D, Banerjee, A, Mateos, M-V & Krishnan, A 2021, ' Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study ', The Lancet, vol. 398, no. 10301, pp. 665-674 . https://doi.org/10.1016/S0140-6736(21)01338-6
LANCET
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myelo
Autor:
Hareth Nahi, Shigeki Ito, Shinsuke Iida, Maria-Victoria Mateos, Kihyun Kim, Nizar J. Bahlis, Saad Z. Usmani, Su-Peng Yeh, Ming Qi, Chang-Ki Min, Christoph Heuck, Katharine S. Gries, Xiang Qin, Takayuki Ishikawa, Dolly A. Parasrampuria
Publikováno v:
Annals of Hematology
The phase 3 COLUMBA study demonstrated noninferiority of subcutaneous daratumumab (DARA SC) to intravenous daratumumab (DARA IV) in relapsed or refractory multiple myeloma. We present a subgroup analysis of Asian patients from COLUMBA. Eligible patie
Autor:
Peter M. Voorhees, Michael Rosenzweig, S. Vincent Rajkumar, Robert Z. Orlowski, Jeffrey A. Zonder, Sandi Fredette Hita, Jason Valent, Natalie S. Callander, Rachael Sexton, Paul G. Richardson, Antje Hoering, Saad Z. Usmani, Swog Trial Investigators, Sikander Ailawadhi, Brian G.M. Durie, Madhav V. Dhodapkar, Todd M. Zimmerman, Brea Lipe
Publikováno v:
The Lancet Haematology. 8:e45-e54
Summary Background The introduction of immunomodulatory agents, proteasome inhibitors, and autologous haematopoietic stem-cell transplantation has improved outcomes for patients with multiple myeloma, but patients with high-risk multiple myeloma have
Autor:
Martin Kaiser, Baldeep Wirk, Monika Engelhardt, Bruno Paiva, Laurent Garderet, S. Vincent Rajkumar, Maria-Victoria Mateos, Philippe Moreau, Carlos Fernández de Larrea, Robert A. Kyle, Jo Caers, Wilson I. Gonsalves, Hermann Einsele, Hartmut Goldschmidt, Giampaolo Merlini, Suzanne Lentzch, Ashraf Badros, Saad Z. Usmani, Joan Bladé, Pellegrino Musto, Fredrik Schjesvold, Pieter Sonneveld, Jesús F. San Miguel, Laura Rosiñol, Gösta Gahrton, Patrick Hayden, Enrique M. Ocio, Brian G.M. Durie, Sascha A. Tuchman
Publikováno v:
Blood Cancer J . 2021 Dec 2;11(12):192
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Blood Cancer Journal
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (12), ⟨10.1038/s41408-021-00587-0⟩
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, 11(12):192. Nature Publishing Group
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Blood Cancer Journal
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (12), ⟨10.1038/s41408-021-00587-0⟩
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, 11(12):192. Nature Publishing Group
Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position pa
Autor:
Carolyn C. Jackson, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Natalie S. Callander, Parameswaran Hari, Yi Lin, Ravi Vij, R. Frank Cornell, Ankit Kansagra, Jennifer Marino, Luciano J. Costa, Ehsan Malek, Hong Tian, Saad Z. Usmani, Shaji Kumar, Mark A. Fiala, Saurabh Chhabra, Thomas Martin, Sundar Jagannath, Yubin Kang, Kelly N. Godby, Jesus G. Berdeja, Michaela Liedtke, Amarendra K. Neppalli
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(5)
BACKGROUND In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) therapy, showed encouraging efficacy in US patients with multiple myeloma (M
Autor:
Sen Hong Zhuang, Elizabeth O'Donnell, Syed Rizvi, Saad Z. Usmani, Myo Htut, Jenna D. Goldberg, Jesus G. Berdeja, Xiaoling Wu, Abhinav Deol, David Avigan, Andrzej Jakubowiak, Jordan M. Schecter, Dong Geng, Muhammad Akram, Parameswaran Hari, William Deraedt, Indrajeet Singh, Farah Hossain, Deepu Madduri, Sundar Jagannath, Tzu-Min Yeh, Mounzer Agha, Jeffrey R. Infante, Carolyn C. Jackson, Nikhil C. Munshi, Alicia J. Allred, Frank Fan, Marlene J Carrasco-Alfonso, A. Keith Stewart, Arnob Banerjee, Yi Lin, Enrique Zudaire, Yunsi Olyslager, Alexander M. Lesokhin, Adam D. Cohen, Thomas Martin
Publikováno v:
Lancet (London, England). 398(10297)
Summary Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients wi
Autor:
Lotfi Benboubker, Saad Z. Usmani, Shinsuke Iida, Jordan M. Schecter, Maria-Victoria Mateos, Christopher Chiu, Lisa O'Rourke, Ludek Pour, Michele Cavo, Nizar J. Bahlis, Gordon Cook, Jacob P. Laubach, Katja Weisel, Andrew Spencer, Sung-Soo Yoon, Ajay K. Nooka, Meletios A. Dimopoulos, Xiang Qin, Jon Ukropec
Publikováno v:
Haematologica
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Efficacy and safety of daratumumab was analyzed according to age g
Autor:
Ryan Jacobs, Jing Ai, Olivia Copelan, Brittany K. Ragon, Zainab Shahid, James T. Symanowski, Jiaxian He, Saad Z. Usmani, Michael R. Grunwald, Nilanjan Ghosh, Thomas G. Knight, Jigar Trivedi, Srinivasa R. Sanikommu, Peter E. Clark, Candace Butler
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:785-790
Hemorrhagic cystitis (HC) is a common and important complication of allogeneic hematopoietic cell transplantation (HCT). Reactivation of BK virus is its most common cause. The more intense immunosuppressive regimens administered to recipients of graf
Autor:
Adam B. Cohen, Yunsi Olyslager, Carolyn C. Jackson, Mounzer Agha, Saad Z. Usmani, Jesus G. Berdeja, Muhammad Akram, Arnob Banerjee, Andrzej Jakubowiak, Alicia J. Allred, Thomas Martin, William Deraedt, Parameswaran Hari, Deepu Madduri, Yi Lin, Lida Bubuteishvili Pacaud, Tzu-Min Yeh, Sundar Jagannath, Xiaoling Wu, Enrique Zudaire
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S15-S16
Background Ciltacabtagene autoleucel (cilta-cel) is a CAR-T cell therapy with two B-cell maturation antigen–targeting single-domain antibodies. The phase 1b/2 CARTITUDE-1 study is evaluating cilta-cel in patients (pts) with RRMM. Here we report upd
Autor:
Mounzer Agha, Saad Z. Usmani, Alicia J. Allred, Xiaoling Wu, Enrique Zudaire, Thomas Martin, Jesus G. Berdeja, Arnob Banerjee, Muhammad Akram, Deepu Madduri, Sundar Jagannath, William Deraedt, Andrzej Jakubowiak, Tzu-Min Yeh, Adam D. Cohen, Yunsi Olyslager, Carolyn C. Jackson, Marlene Carrasco-Alfonso, Yi Lin, Parameswaran Hari
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S422-S423
Context Cilta-cel, a CAR-T cell therapy containing 2 BCMA-targeting single domain antibodies designed to confer high avidity binding, is being evaluated in the CARTITUDE-1 phase 1b/2 study. Objectives Provide updated results with a longer duration (m